[{"id":"70160198-3c38-445a-bd28-c334947e8c40","acronym":"CAR-HiRiSMM","url":"https://clinicaltrials.gov/study/NCT06574126","created_at":"2025-02-27T08:14:40.308Z","updated_at":"2025-02-27T08:14:40.308Z","phase":"Phase 2","brief_title":"Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma","source_id_and_acronym":"NCT06574126 - CAR-HiRiSMM","lead_sponsor":"PETHEMA Foundation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 09/30/2032","primary_completion_date":" 09/30/2032","study_txt":" Completion: 09/30/2032","study_completion_date":" 09/30/2032","last_update_posted":"2024-10-26"},{"id":"8e484efc-2bb4-4551-a333-691298e0bf81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05767359","created_at":"2023-03-14T14:01:36.331Z","updated_at":"2024-07-02T16:35:45.349Z","phase":"Phase 2","brief_title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","source_id_and_acronym":"NCT05767359","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2040","study_completion_date":" 01/15/2040","last_update_posted":"2023-06-19"},{"id":"745efccf-4213-4879-bbd4-a904c2add42c","acronym":"CARTIFAN-1","url":"https://clinicaltrials.gov/study/NCT03758417","created_at":"2021-01-18T18:28:26.452Z","updated_at":"2024-07-02T16:35:58.499Z","phase":"Phase 2","brief_title":"A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03758417 - CARTIFAN-1","lead_sponsor":"Nanjing Legend Biotech Co.","biomarkers":" CD8 • IL6 • IL2RA • CD4 • IL10","pipe":"","alterations":" ","tags":["CD8 • IL6 • IL2RA • CD4 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 02/16/2026","primary_completion_date":" 02/16/2026","study_txt":" Completion: 02/16/2026","study_completion_date":" 02/16/2026","last_update_posted":"2022-12-28"}]